Sign in
TerminatedPhase 1

Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, Brooklyn, Durham, New York, and St Louis, United StatesSee the 6 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
5 people enrolled
Started
6 Dec 2023
Ended
25 Oct 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)
  • Inhaled Medical air
Record updated
26 May 2026
Why it stopped
Due to low enrollment, the study was halted early.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • All patients (age 18 and older) will be eligible for inclusion if they meet all of the following consensus criteria for sepsis and ARDS3,4 or if they meet the criteria for pneumonia as described below
  • Patients with sepsis are defined as those with life-threatening organ dysfunction caused by a dysregulated host response to infection:; Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system; Increase in Sequential Organ Failure Assessment (SOFA) Score ≥ 2 over baseline
  • ARDS is defined when all four of the following criteria are met:; A PaO2/FiO2 ratio ≤ 300 with at least 5 cm H2O positive end-expiratory airway pressure (PEEP); Bilateral opacities on frontal chest radiograph (not fully explained by effusions, lobar/lung collapse, or nodules) within 1 week of a known clinical insult or new or worsening respiratory symptoms; A need for positive pressure ventilation by an endotracheal or tracheal tube; Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor is present
  • Pneumonia (without ARDS or sepsis) will be defined as a unilateral or bilateral lung infiltrate on chest X-ray or chest CT (not fully explained by effusions, lobar/lung collapse or nodules) in the setting of receiving mechanical ventilation, a new suspected respiratory infection, an increase in SOFA score less than 2 at the time of randomization (baseline)
  • Pneumonia (with sepsis, without ARDS) will be defined as a unilateral or bilateral lung infiltrate on chest X-ray or chest CT (not fully explained by effusions, lobar/lung collapse or nodules) in the setting of receiving mechanical ventilation and a new suspected respiratory infection with an increase in SOFA score of ≥ 2 over baseline at the time of randomization. Pneumonia with bilateral opacities, PaO2/FiO2 ratio ≤ 300, or an increase in SOFA score greater than or equal to 2 over baseline will continue to be considered ARDS and sepsis

Who cannot take part

  • Coronary artery bypass graft (CABG) surgery within 30 days
  • Stroke (ischemic or hemorrhagic) within the prior 1 month, cardiac arrest requiring CPR within the prior 72 hours, or inability to assess mental status following cardiac arrest
  • Use of inhaled pulmonary vasodilator therapy (eg. nitric oxide [NO] or prostaglandins)
  • Concurrent participation in other investigational drug study
  • Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
  • Acute myocardial infarction (MI) or acute coronary syndrome (ACS) within the last 90 days
  • Angina pectoris or use of nitrates with activities of daily living
  • Severe cardiopulmonary disease classified as New York Heart Association (NYHA) class IV
  • Diffuse alveolar hemorrhage from vasculitis
  • Hemoglobin < 7.0 g/dL
  • Age less than 18 years
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Greater than 168 hours since ARDS onset
  • Pregnant or breastfeeding
  • Prisoner
  • No consent/inability to obtain consent or appropriate legal representative not available
  • Physician refusal to allow enrollment in the trial
  • Moribund patient not expected to survive 24 hours
  • No arterial line or central line/no intent to place an arterial or central line
  • No intent/unwillingness to follow lung protective ventilation strategy
  • Severe hypoxemia defined as SpO2 < 95 or PaO2 < 90 on FiO2 ≥ 0.9
  • Subjects who are Jehovah's Witnesses or are otherwise unable or unwilling to receive blood transfusions during hospitalization
  • Burns > 40% total body surface area
  • Severe airway inhalational injury
  • Use of high frequency oscillatory ventilation
  • Use of extracorporeal membrane oxygenation (ECMO)

Where in United States

  • Brigham and Women's HospitalBoston, United States
  • Massachusetts General HospitalBoston, United States
  • New York-Presbyterian/Brooklyn Methodist HospitalBrooklyn, United States
  • Duke University HospitalDurham, United States
  • Weill Cornell Medical CollegeNew York, United States
  • Washington UniversitySt Louis, United States

About the trial

What the trial wants to find out

This study is a multi-center, randomized, partially double-blind, and placebo-controlled Phase Ib clinical trial of inhaled CO (iCO) for the treatment of sepsis-induced acute respiratory distress syndrome (ARDS). The purpose of this study is to evaluate the safety and accuracy of a Coburn-Forster-Kane (CFK) equation-based personalized iCO dosing algorithm to achieve a target carboxyhemoglobin (COHb) level of 6-8% in patients with sepsis-induced ARDS. We will also examine the biologic readouts of low dose iCO therapy in patients with sepsis-induced ARDS.

The 2 groups in the trial

  • Inhaled Carbon MonoxideTreatment being tested

    Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.

    Treatment: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)

  • Medical airPlacebo, for comparison

    Inhaled Medical Air for up to 90 minutes daily for 3 days.

    Treatment: Inhaled Medical air

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib Trial of Inhaled Carbon Monoxide for the Treatment of Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
Record updated
26 May 2026